Lacosamida Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes. This selective action reduces the persistent sodium current, limiting abnormal neuronal firing that leads to seizures while preserving normal rapid channel activity.

The specific dosing regimen for Lacosamida Fresenius Kabi is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. Healthcare professionals should follow local guidelines and individualize therapy accordingly.

Safety data for lacosamide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate potential benefits against risks and consider alternative treatments when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide offers a unique mechanism by enhancing slow sodium‑channel inactivation, differing from many agents that block fast inactivation. This can provide additive seizure control when combined with other antiepileptics, and it is often well tolerated, though individual response varies compared with alternatives such as carbamazepine or levetiracetam.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

Lacosamida Fresenius Kabi is given as an intravenous infusion. The infusion rate and total dose are set by the prescriber, typically administered over a defined period in a clinical setting to ensure controlled plasma concentrations.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential arrhythmias, severe skin reactions (e.g., Stevens‑Johnson syndrome), respiratory depression, and rare cases of suicidal ideation. Patients should be monitored closely for these events, especially during initiation or dose changes.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid use. Caution is advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications that could exacerbate cardiac or CNS effects.